Published in Cancer Weekly, January 11th, 2005
The data were presented in sessions at the annual meeting of the American Society of Hematology in San Diego, California.
In the first study, investigators from Roswell Park Cancer Institute showed that Genasense or rituximab used alone significantly increased mean survival of mice implanted with NHL (by 130% and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.